Exposing the DEA's Marijuana Licensing Scheme
A recent discovery has shed light on the DEA's agreements, confirming MMJ BioPharma Cultivation's long-standing argument that the agency's rules hinder the production of pharmaceutical-grade cannabis for FDA-authorized clinical research.
Newly uncovered DEA agreements have revealed a fatal flaw in America's cannabis research policy, supporting MMJ BioPharma Cultivation's case and explaining why scientific progress has been stalled for nearly a decade.
A recently disclosed memorandum of understanding between the DEA and a registered marijuana cultivator has revealed the DEA fatal flaw at the heart of America's cannabis research policy.
This exposé highlights the contradiction within the DEA's rules, making it impossible for companies to legally produce pharmaceutical-grade cannabis.
Author's summary: DEA's rules hinder cannabis research.
More News
- DansLesCoulisses.com | Pour en savoir plus que les autres!
- Katy Perry en couple avec Justine Trudeau : l’ex-Premier ministre la regarde
- Big Bash League upcoming match schedule
- Ryder — Founder and Leader of the PAW Patrol Team
- Ryder Tully Instagram Bio Summary
- [Odds on Lando Norris winning SPOTY 2026 tumble as F1 world champion battles Luke Littler and Rory McIlroy for BBC award]
- The 400 million reasons behind Cricket Australia’s Big Bash sale
- [Luke Skywalker - Wikipedia summary]
- Hockey30 | Le Mouton Noir du Hockey
- Women's Big Bash League: Brisbane Heat's Winless Season Ends With 7-Wicket Loss Against Perth Scorchers